WPD Pharmaceuticals has reported positive data from the Phase I clinical trial of Berubicin drug to treat glioblastoma multiforme (GBM).
The clinical trial of Berubicin drug, conducted by pharmaceutical company Reata Pharmaceuticals, found that a patient remained cancer-free.
At present, no approved effective therapies are available to treat GBM, an aggressive type of brain cancer.
WPD Pharmaceuticals CEO Mariusz Olejniczak said: “We are delighted to provide this update on Berubicin’s potential capabilities as we continue to develop the drug. We are very encouraged by these results and remain hopeful in our efforts to treat glioblastoma multiforme.
“We are looking forward to initiating the Phase II clinical trial in the second half of this year with our partner, CNS Pharmaceuticals.”
In the Phase I trial of the drug, 44% of patients reported a statistically significant improvement in progression-free survival.
Disease control rate comes from 11 out of 25 evaluable patients with stable disease, plus responders.
During the trial, one patient experienced a durable complete response, defined as the disappearance of all signs of cancer in response to treatment, by the National Cancer Institute.
The initial trial took place in 2006, and the patient has remained cancer-free for over 13 years, as of February.
Last month, WPD Pharmaceuticals and CNS Pharmaceuticals announced plans to initiate a Phase I clinical trial for Berubicin, an anthracycline, in paediatric brain cancer at the Children’s Memorial Health Institute in Poland.
WPD has ten novel drug candidates, and four of them are in the clinical development stage.